NCT00093444View on ClinicalTrials.gov

Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

January 31, 2010

Conditions

Liver CancerMetastatic Cancer

Interventions

DRUG

lyso-thermosensitive liposomal doxorubicin

PROCEDURE

radiofrequency ablation

Trial Locations (2)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

Unknown

Queen Mary Hospital - Hong Kong, Hong Kong

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00093444 - Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | Biotech Hunter | Biotech Hunter